The latest breaking news ireland story on healthcare spending has put the spotlight on the State’s growing bill for weight-loss injections. New figures show the HSE spent more than €200 million on Ozempic and Saxenda over less than three years, with average daily spending last year reaching about €550,000 for patients covered under free drugs schemes.
The data points to a sharp rise in demand, especially as more patients accessed these medications through the Long-Term Illness scheme, medical cards and the Drugs Payment Scheme. It also adds to wider debate in ireland health news and ireland government news around how public money is being used as demand for GLP-1 medicines continues to climb.
How much the HSE spent on the drugs
According to the released records, total HSE spending on Ozempic and Saxenda between January 2023 and September 2025 came to just under €212 million. Much of that was linked to Ozempic, which is funded for adults with diabetes rather than for weight management.
- €161.9 million was spent on Ozempic under the Long-Term Illness scheme
- €41.2 million was spent on Ozempic and Saxenda through medical cards
- €8.8 million was spent under the Drugs Payment Scheme
That spending trend is likely to feature prominently in ireland current affairs as policymakers weigh rising pharmaceutical costs against growing clinical demand.
Who is getting the medication?
Roughly 80,000 patients received the drugs under free schemes in 2025, according to the records. The number of patients using the injections at taxpayers’ expense has risen significantly since 2023, with uptake under the Long-Term Illness scheme alone up by 34%.
Ozempic has become especially notable in ireland news today because, while often associated with weight loss, it is only reimbursed by the HSE for patients diagnosed with diabetes. Saxenda, by contrast, is funded specifically for weight management through certain schemes.
Read More: Healthcare pressures continue to reshape public spending priorities
Regional differences revealed in breaking news ireland figures
The figures also show clear regional variation in how widely these medicines are being used. Kildare and West Wicklow recorded some of the highest numbers, alongside North Dublin and Galway, while West Cork, Roscommon and Dun Laoghaire were among the lowest.
For medical card patients, Galway had the highest number receiving the drugs during the first eight months of 2025, followed by Limerick. These regional gaps may become part of broader discussion in dublin news, cork news, galway news and limerick news as local services assess demand and prescribing patterns.
Highest and lowest usage areas
- Highest overall use included Kildare and West Wicklow, North Dublin and Galway
- Lowest overall use included West Cork, Roscommon and Dun Laoghaire
- Galway led among medical card patients, followed by Limerick
Explore: Regional trends are increasingly shaping Ireland’s public service debates
What happens next for public funding?
The HSE has said processes are underway that will help determine whether newer drugs such as Mounjaro and Wegovy could eventually be reimbursed under public schemes. That means this developing issue may remain part of ireland updates and ireland national news for some time.
The central policy question is whether the State can continue to absorb rising demand for high-cost medicines while keeping access fair and clinically appropriate. With obesity treatment, diabetes care and medicine reimbursement all intersecting, the issue sits squarely within ireland politics news, ireland economy news and ireland health news.
Read More: Why rising public healthcare costs are becoming a bigger national issue
Conclusion
This breaking news ireland update highlights just how quickly spending on GLP-1 medications has escalated. With more patients using Ozempic and Saxenda and new drugs under review, the HSE now faces growing pressure to balance medical need, cost control and long-term public health strategy. The takeaway is clear: spending on these injections is no longer a niche issue, but a major healthcare and budget story with national implications.
